Phase 3 Endometriosis Trial, Recruiting NCT04356664 Sponsor: Hopital Foch Condition: Endometriosis
Back to Endometriosis

Phase 3 Endometriosis Trial, Recruiting

NCT04356664
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman between 18 and 35 years old (inclusive) who has been diagnosed with endometriosis and/or adenomyosis
  • You have already gone through IVF (in vitro fertilisation) or ICSI (a type of IVF where a single sperm is injected into an egg), where all embryos were frozen, and a planned transfer of a frozen embryo at the blastocyst stage is coming up
  • You have a normal uterine cavity (the inside of your womb has no abnormalities)
  • You have had an MRI scan that confirms endometriosis and/or adenomyosis at the time of joining the trial
  • You have signed a consent form agreeing to take part
  • You are covered by a health insurance plan

Who may not be able to join:

  • You are under 18 or 36 years of age or older
  • Your Body Mass Index (BMI) is over 35
  • You have had 2 or more previous failed embryo implantation attempts
  • You have certain changes or growths inside your womb, such as scar tissue, polyps, fibroids, abnormal thickening of the womb lining, or a build-up of blood in the womb
  • You have a known blockage or fluid build-up in one or both fallopian tubes (known as hydrosalpinx)
  • Your MRI scan does not show signs of endometriosis or adenomyosis
  • You have a known allergy or sensitivity to any of the medications used in this trial, including: GnRH or similar hormone medicines (such as Decapeptyl), oestrogen (estradiol), progesterone, aspirin or anti-inflammatory painkillers (NSAIDs), folic acid, the antibiotics cefixime (or similar cephalosporin antibiotics), or levofloxacin (or similar quinolone antibiotics)
  • You have a history of tendon problems caused by a type of antibiotic called fluoroquinolones
  • You have epilepsy
  • You have a known allergy to MRI contrast dye
  • You have been diagnosed with, or are suspected to have, breast cancer — or have a history of breast cancer
  • You have been diagnosed with, or are suspected to have, cancer of the reproductive organs — or have a history of such cancer
  • You have any cancer that is known or suspected to be worsened by oestrogen
  • You have unexplained vaginal bleeding that has not been investigated
  • You have untreated abnormal thickening of the womb lining (endometrial hyperplasia)
  • You have a history of blood clots in the veins (such as deep vein thrombosis or pulmonary embolism), or currently have one
  • You have recently had or currently have a blood clot affecting arteries, such as a heart attack or stroke
  • You have an active liver disease, or a history of liver disease where liver test results have not returned to normal
  • You have severe kidney disease
  • You have severe heart failure that is not well controlled
  • You currently have an active stomach or duodenal ulcer
  • You have a history of asthma triggered by aspirin or similar anti-inflammatory medicines
  • You have received the hormone treatment Decapeptyl (a GnRH agonist) within the 6 months before your planned embryo transfer
  • You are currently pregnant or breastfeeding
  • You are under legal guardianship or have restrictions on your personal freedom (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Paul Pirtea, Dr, Hopital Foch

Phone: 0033146251175

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Hopital Foch
Registry
ClinicalTrials.gov
Start date
18 March 2021
Est. completion
18 June 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Clinical pregnancy rate in both groups at last visit ultrasound

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov